ZNF608

Across TCGA pan-cancer cohorts, ZNF608 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF608 data layer compared with 26 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZNF608 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF608 expression acts as an unfavorable survival marker.

LUAD, PRAD, and ACC are the cancer types where ZNF608 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.079	0.788	<.001	18	view →
PRAD	DFS	Median	All	0.447	0.888	<.001	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
BRCA	OS	Median	All	0.756	0.963	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZNF608–LUAD (OS)

Open the LUAD breakdown →